JN’s research and development organization draws upon expertise in multiple discovery platforms. We have outlined a number of early-stage development that include three novel CNS vaccines and diagnostics to ﬁght Stroke and Alzheimer’s diseases. An anti-TIA/Stroke an oral therapeutic vaccine and point-care settings diagnostics for CNS diseases are in process of human trials. We also have programs progressing through development that seek to expand existing products with newly identiﬁed uses and indications. We are hopeful for U.S. approval in 2012 for Meningococcal conjugate vaccine and our human trial outcome will be reviewed at an FDA advisory committee meeting. Our NMDA therapeutics, under investigation is targeted for regulatory ﬁling in the ﬁrst half of 2013.
Herpes Clinical studies
Genital herpes Vaccine (GH) human studies:
Type 2 (HSV-2) is a suitable target for a vaccine, despite available antiviral therapies, because the virus causes lifelong infection and significant medical and psychosocial morbidity.
GH non-IND Phase-1 non-IND Study: This study has been initiated in Cambodia using Herpes infected and control subjects.
TIA / Ischemic Stroke Clinical studies
Stroke Vaccine Phase-1 non-IND human study:
This first stage of stroke clinical trials is designed to gain basic safety and pharmacologic information. Single or multiple conservative doses of the drug will be administered to volunteers in South Africa.